Hunan Cancer Hospital

Fuzuloparib in combination with apatinib versus fuzuloparib alone for recurrent ovarian cancer: a randomized, open-label, phase 2 trial

A randomized, open-label, phase 2 trial assessed fuzuloparib (a PARP inhibitor) plus apatinib (a vascular endothelial growth factor receptor [VEGFR] inhibitor) versus fuzuloparib alone in patients with recurrent ovarian cancer (ROC). Patients with ROC who had failed ≥ 2 lines of...

A cfDNA fragmentomics-based liquid biopsy assay for early detection of oral cancer

Abstract Background Early detection of oral cancer improves outcomes, but remains limited by the invasiveness and low sensitivity of current screening methods. Methods This study included 342 participants (200 in the training and 142 in the validation cohorts). Plasma cfDNA under...

CACA guidelines for the management of adult cancer pain

Abstract Cancer pain, one of the most prevalent and distressing symptoms in cancer patients, is closely associated with cancer diagnosis, therapeutic interventions, quality of life, and survival outcomes. Effective cancer pain management requires multidisciplinary collaborative a...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Exercise-containing multimodal prehabilitation on functional outcome of patients with hepatobiliary and pancreatic cancer after surgery: a meta-analysis

Hepatobiliary and pancreatic (HBP) cancers often require complex surgeries that lead to functional decline and poor quality of life (QoL). Exercise-containing multimodal prehabilitation has gained attention as a potential strategy to enhance perioperative outcomes. This meta-anal...

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer

Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EV...

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer

Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites...

Real-world evidence of immunotherapy in older adults with advanced non-small cell lung cancer: a retrospective cohort study

Older patients are underrepresented in clinical trials of immunotherapy for driver gene-negative advanced non-small cell lung cancer (NSCLC). This study aimed to investigate real-world efficacy and safety of immunotherapy in this population. Clinical data from 649 patients aged ≥...